

Deborah N Kalkman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3305472/publications.pdf>

Version: 2024-02-01

42
papers

665
citations

687363

13
h-index

580821

25
g-index

43
all docs

43
docs citations

43
times ranked

1100
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. <i>European Heart Journal</i> , 2022, 43, e17-e25.	2.2	92
2	Residual inflammatory risk and the impact on clinical outcomes in patients after percutaneous coronary interventions. <i>European Heart Journal</i> , 2018, 39, 4101-4108.	2.2	89
3	Residual Inflammatory Risk in Patients With Low LDL Cholesterol Levels Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2401-2409.	2.8	69
4	1-Year Results of the REMEDEE Registry. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1127-1134.	2.9	45
5	J Curve in Patients Randomly Assigned to Different Systolic Blood Pressure Targets. <i>Circulation</i> , 2017, 136, 2220-2229.	1.6	42
6	Indirect comparison of the efficacy and safety of alirocumab and evolocumab: a systematic review and network meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 225-235.	3.0	40
7	Intensive Blood Pressure Lowering in Patients With and Patients Without Type 2 Diabetes: A Pooled Analysis From Two Randomized Trials. <i>Diabetes Care</i> , 2018, 41, 1142-1148.	8.6	37
8	Impact of coronary artery disease and percutaneous coronary intervention in women undergoing transcatheter aortic valve replacement: From the WIN-TAVI registry. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 1124-1131.	1.7	22
9	Variation in Coronary Anatomy in Adult Patients Late After Arterial Switch Operation: A Computed Tomography Coronary Angiography Study. <i>Annals of Thoracic Surgery</i> , 2013, 96, 1390-1397.	1.3	21
10	1-Year Clinical Outcomes of All-Comer Patients Treated With the Dual-Therapy COMBO Stent. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1969-1978.	2.9	21
11	One year clinical outcomes in patients with insulin-treated diabetes mellitus and non-insulin-treated diabetes mellitus compared to non-diabetics after deployment of the bio-engineered COMBO stent. <i>International Journal of Cardiology</i> , 2017, 226, 60-64.	1.7	20
12	Impact of Baseline Atrial Fibrillation on Outcomes Among Women Who Underwent Contemporary Transcatheter Aortic Valve Implantation (from the Win-TAVI Registry). <i>American Journal of Cardiology</i> , 2018, 122, 1909-1916.	1.6	18
13	Implantation techniques (predilatation, sizing, and post-dilatation) and the incidence of scaffold thrombosis and revascularisation in lesions treated with an everolimus-eluting bioresorbable vascular scaffold: insights from the AIDA trial. <i>EuroIntervention</i> , 2018, 14, e434-e442.	3.2	14
14	Evaluation of clinical outcomes after COMBO stent treatment in patients presenting with acute coronary syndrome. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, E31-E37.	1.7	13
15	Two-year clinical outcomes of patients treated with the dual-therapy stent in a 1000 patient all-comers registry. <i>Open Heart</i> , 2017, 4, e000634.	2.3	13
16	Clinical outcomes after percutaneous coronary intervention with the COMBO stent versus Resolute Integrity and PROMUS Element stents: a propensity-matched analysis. <i>EuroIntervention</i> , 2017, 13, 1202-1209.	3.2	11
17	1-Year Clinical Outcomes of All-Comers Treated With 2 Bioresorbable Polymer-Coated Sirolimus-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 820-830.	2.9	10
18	Predictors of residual tricuspid regurgitation after percutaneous closure of atrial septal defect. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, 225-232.	1.2	9

#	ARTICLE	IF	CITATIONS
19	Three-year clinical outcomes after dual-therapy COMBO stent placement: Insights from the REMEDEE registry. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 342-347.	1.7	8
20	Temporal trends, determinants, and impact of high-intensity statin prescriptions after percutaneous coronary intervention. <i>American Heart Journal</i> , 2019, 207, 10-18.	2.7	7
21	The relationship of pre-procedural Dmax based sizing to lesion level outcomes in Absorb BVS and Xience EES treated patients in the AIDA trial. <i>International Journal of Cardiovascular Imaging</i> , 2019, 35, 1189-1198.	1.5	6
22	Residual angina in female patients after coronary revascularization. <i>International Journal of Cardiology</i> , 2019, 286, 208-213.	1.7	6
23	Feasibility and Utility of a Cardiovascular Risk Screening Tool in Women Undergoing Routine Gynecology Evaluation. <i>Journal of Women's Health</i> , 2020, 29, 1150-1159.	3.3	6
24	Final five-year results of the REMEDEE Registry: Real-world experience with the dual-therapy COMBO stent. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 98, 503-510.	1.7	6
25	Atrial fibrillation, with ACS and PCI: walking a tightrope. <i>European Heart Journal</i> , 2019, 40, 1563-1566.	2.2	5
26	Comparison of One-Year Outcomes in Patients >75 Versus ≤75 Years With Coronary Artery Disease Treated With COMBO Stents (From The MASCOT Registry). <i>American Journal of Cardiology</i> , 2020, 127, 1-8.	1.6	5
27	Five-year follow-up of the endothelial progenitor cell capturing stent versus the paxlitaxel-eluting stent in de novo coronary lesions with a high risk of coronary restenosis. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 1212-1218.	1.7	4
28	A paradox in sex-specific clinical outcomes after bioresorbable scaffold implantation: 2-year results from the AIDA trial. <i>International Journal of Cardiology</i> , 2020, 300, 93-98.	1.7	4
29	Sex differences in 1-year clinical outcomes after percutaneous coronary intervention with COMBO stents: From the COMBO collaboration. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 797-804.	1.7	4
30	Does the novel delivery system for the STENTYS self-apposing coronary stent increase the risk of stent edge dissections? Optical coherence tomography post stent findings. <i>Expert Review of Medical Devices</i> , 2018, 15, 157-165.	2.8	3
31	Early discontinuation of dual antiplatelet therapy in patients treated with the bio-engineered pro-healing sirolimus-eluting (COMBO) stent. <i>Cardiovascular Revascularization Medicine</i> , 2018, 19, 373-375.	0.8	3
32	Long-Term Performance of the COMBO Dual-Therapy Stent: Results from the REMEDEE Registry. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 567-570.	0.8	3
33	1-Year Outcomes with COMBO Stents in Small-Vessel Coronary Disease: Subgroup Analysis From the COMBO Collaboration. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 1542-1547.	0.8	3
34	One-Year COMBO Stent Outcomes in Acute Coronary Syndrome: from the COMBO Collaboration. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 309-320.	2.6	2
35	Current evidence for the safety and efficacy of the bio-engineered dual therapy COMBO stent. <i>Minerva Cardiology and Angiology</i> , 2018, 66, 262-272.	0.7	2
36	1-Year Clinical Performance of COMBO Stent Versus Xience Stent in All-Comers Patients With Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 102-103.	2.9	1

#	ARTICLE	IF	CITATIONS
37	1-year results after PCI with the COMBO stent in all-comers in Asia versus Europe: Geographical insights from the COMBO collaboration. <i>International Journal of Cardiology</i> , 2020, 307, 17-23.	1.7	1
38	TCT-796 A paradox in sex-specific clinical outcomes after bioresorbable scaffold implantation: 2-year results from the AIDA trial. <i>Journal of the American College of Cardiology</i> , 2018, 72, B316-B317.	2.8	0
39	Response by Kalkman et al to Letter Regarding Article, "œJ Curve in Patients Randomly Assigned to Different Systolic Blood Pressure Targets: An Experimental Approach to an Observational Paradigm" Circulation, 2018, 137, 2549-2550.	1.6	0
40	The influence of implantation techniques on lesion oriented-outcomes in Absorb BVS and Xience EES lesions treated in routine clinical practice at complete three year follow-up: AIDA trial QCA substudy. <i>International Journal of Cardiovascular Imaging</i> , 2020, 36, 565-575.	1.5	0
41	One-year clinical outcomes in patients with chronic kidney disease treated with COMBO stents: From the COMBO collaboration. <i>Catheterization and Cardiovascular Interventions</i> , 2020, , .	1.7	0
42	Interventions in Ischemic Heart Disease. , 2021, , 93-108.		0